This annual conference, held in cooperation with FDA, brings together the regulated industries and the regulators who are concerned about the advertising and promotion of prescription drugs and medical devices. Included are updates from all four FDA medical products centers, insights into some of the practical issues facing regulated industry,
and an opportunity in breakout sessions for active and lively discussions.
This is the only advertising conference with a breakout session for
veterinary medicine.

Program Highlights
Below is a list of sessions scheduled for this year's agenda:

> Enforcement Policy Updates from FDA Centers: CBER, CDER, CDRH, CVM
> FDA’s Draft Guidance on Dissemination of Reprints
> FDA’s Initiatives in Communicating Risk Information
> Update on Direct-to-Consumer Advertising
> Defining Scientific Exchange, Pre-Approval “Promotion”, Substantial
   Evidence and Fair Balance
> Controversy over Conflict of Interest in CME –
   Will Industry Funding Disappear?
> How to Conduct an Advertising Review
> Update on Off-label Settlements – What is DOJ Concerned About?
> The New PhRMA Code
> Complying with Corporate Integrity Agreements
> Q&A with FDA Speakers
> Plus so much more!

Who Should Attend?
The conference has been developed for advanced and experienced regulatory, legal, public relations, marketing, economic, sales, compliance and management professionals in pharmaceutical, veterinary medicine, biologics and medical device companies and organizations, as well as consultants in the areas of advertising, public relations, legal and marketing communications.

Silver Sponsor

Networking Reception
Brought to you in part by

Copyright © 2008, The Food and Drug Law Institute    
1155 15 Street NW, Suite 800 | Washington, DC | 20005    
phone (800) 956-6293 | (202) 371-1420 | fax (202) 371-0649    
comments@fdli.org